Company intelligence / Profile preview

GambitBio

Oxford, England, United Kingdomgambit.bio ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

GambitBio is developing a low-cost, at-home saliva-based lateral flow test for early cancer detection, with the lead program targeting prostate cancer. The company has developed two prototypes and is preparing for mass production through partnerships with manufacturers. Commercial launch of the first product is anticipated around 2026 or 2027. No clinical trial results have been published yet.

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic test (Lateral flow assay)Biomarker-based detection technology
Industry: Protein Biomarker Diagnostics

Partnerships

Partnership discussions underway with a lateral flow test manufacturer for scaling up production

Beyond the preview

Go deeper on GambitBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GambitBio.

Explore the full profile